SER
Serina Therapeutics, Inc.
US
Income statement
| Metric | TTM | 2024 | 2023 | 2022 | 2020 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 116.0K | 56.0K | 3.2M | 500.0K | 54.0K |
| Cost of Revenue | 50.0K | 194.0K | 90.0K | — | 1.3M |
| Gross Profit | 66.0K | (138.0K) | 3.1M | 500.0K | (1.2M) |
| Operating Expenses | |||||
| R&D Expense | 12.1M | 7.5M | 2.4M | 1.6M | 3.6M |
| SG&A Expense | 11.3M | 9.4M | 3.9M | 1.3M | 5.6M |
| General & Admin Expense | 5.7M | — | 3.9M | 1.3M | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (16.0K) | — | (90.0K) | (91.5K) | — |
| Total Operating Expenses | 23.4M | 16.9M | 6.2M | 2.8M | 9.2M |
| Cost and Expenses | 23.5M | 17.1M | 6.3M | 2.8M | 10.5M |
| Operating Income (EBIT) | (23.4M) | (17.0M) | (3.1M) | (2.3M) | (10.4M) |
| Non-Operating | |||||
| Interest Income | — | — | — | 1.8K | — |
| Interest Expense | 32.0K | 526.0K | 558.0K | 15.9K | 404.0K |
| Net Interest Income | (32.0K) | (526.0K) | (558.0K) | (14.1K) | (404.0K) |
| Other Non-Op Income/Expense | 4.7M | 5.8M | 8.4M | (411.7K) | 8.0K |
| Non-Operating Income (excl Interest) | (4.8M) | (6.4M) | (9.0M) | 395.9K | (412.0K) |
| EBT (Pre-Tax Income) | (18.6M) | (11.2M) | 5.3M | (2.7M) | (10.4M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (18.6M) | (11.1M) | 5.3M | (2.7M) | (10.9M) |
| Earnings from Cont. Ops | (18.6M) | (11.2M) | 5.3M | (2.7M) | (10.4M) |
| Earnings from Discont. Ops | — | — | — | — | (471.0K) |
| Bottom Line Net Income | (18.6M) | (11.1M) | 5.4M | (2.7M) | (10.9M) |
| Per Share | |||||
| Basic EPS | ($1.89) | ($1.51) | $0.63 | ($2.49) | ($10.14) |
| Diluted EPS | ($1.83) | ($1.51) | $0.63 | ($2.49) | ($10.14) |
| Revenue Per Share | $0.01 | $0.01 | $0.37 | $0.46 | $0.05 |
| Shares | |||||
| Basic Shares Outstanding | 10.3M | 7.4M | 8.4M | 1.1M | 1.1M |
| Diluted Shares Outstanding | 10.3M | 7.4M | 8.4M | 1.1M | 1.1M |
| Profitability Metrics | |||||
| EBITDA | (18.5M) | (10.5M) | 5.9M | (2.6M) | (8.7M) |
| D&A | 106.0K | 194.0K | 90.0K | 61.3K | 1.3M |
| EBIT | (18.6M) | (10.7M) | 5.8M | (2.7M) | (10.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2025